Neostigmine
Bloxiverz, Prevduo (neostigmine) is a small molecule pharmaceutical. Neostigmine was first approved as Bloxiverz on 2013-05-31. It is used to treat drug-induced abnormalities, myasthenia gravis, urinary bladder diseases, and urinary retention in the USA. It is known to target acetylcholinesterase.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| nervous system diseases | D009422 |
| urogenital diseases | D000091642 |
| hereditary congenital and neonatal diseases and abnormalities | D009358 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Bloxiverz (generic drugs available since 2015-12-28)
CombinationsPrevduo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Glycopyrrolate
+
Neostigmine methylsulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PREVDUO | Slayback Pharma | N-216903 RX | 2023-02-23 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bloxiverz | New Drug Application | 2023-01-11 |
| neostigmine methylsulfate | ANDA | 2023-06-01 |
| prevduo | New Drug Application | 2023-02-23 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| drug-induced abnormalities | — | D000014 | — |
| myasthenia gravis | EFO_0004991 | D009157 | G70.0 |
| urinary bladder diseases | — | D001745 | N32.9 |
| urinary retention | HP_0000016 | D016055 | R33 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
NEOSTIGMINE METHYLSULFATE, NEOSTIGMINE METHYLSULFATE, DR REDDYS | |||
| 2023-01-21 | CGT | ||
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07A: Parasympathomimetics
— N07AA: Anticholinesterase parasympathomimetics
— N07AA01: Neostigmine
— N07AA51: Neostigmine, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EB: Parasympathomimetics, antiglaucoma preparations and miotics
— S01EB06: Neostigmine
HCPCS
Code | Description |
|---|---|
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg |
Clinical
Clinical Trials
160 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuromuscular blockade | D019148 | 1 | 2 | 5 | 18 | 6 | 31 | ||
| Delayed emergence from anesthesia | D055191 | — | 2 | — | 7 | 4 | 13 | ||
| Anesthesia | D000758 | — | — | 2 | 3 | 1 | 6 | ||
| Post-dural puncture headache | D051299 | — | 1 | 1 | 3 | — | 5 | ||
| Spinal cord injuries | D013119 | EFO_1001919 | 4 | — | — | 1 | — | 5 | |
| Postoperative nausea and vomiting | D020250 | EFO_0004888 | — | — | 1 | 1 | 1 | 3 | |
| Postoperative complications | D011183 | — | — | — | 2 | — | 2 | ||
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | 2 | — | 2 |
| Neoplasms | D009369 | C80 | — | — | — | 2 | — | 2 | |
| Anesthesia recovery period | D000762 | — | — | — | 2 | — | 2 |
Show 23 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| General anesthesia | D000768 | 1 | 1 | 5 | — | 1 | 7 | ||
| Postoperative pain | D010149 | G89.18 | — | 2 | 1 | — | 2 | 4 | |
| Morbid obesity | D009767 | EFO_0001074 | — | 1 | 1 | — | 1 | 2 | |
| Hypospadias | D007021 | EFO_0004209 | Q54 | — | 1 | 1 | — | — | 1 |
| Burns | D002056 | T30.0 | — | — | 1 | — | — | 1 | |
| Muscle weakness | D018908 | HP_0001324 | — | — | 1 | — | — | 1 | |
| Muscle fatigue | D018763 | — | — | 1 | — | — | 1 | ||
| Elective surgical procedures | D017558 | — | — | 1 | — | — | 1 | ||
| Replacement arthroplasty knee | D019645 | — | — | 1 | — | — | 1 | ||
| Replacement arthroplasty hip | D019644 | — | — | 1 | — | — | 1 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | 1 | — | — | — | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | — | 1 |
| Septic shock | D012772 | A48.3 | — | 1 | — | — | — | 1 | |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | 1 | — | — | — | 1 |
| Intra-abdominal hypertension | D059325 | — | 1 | — | — | — | 1 | ||
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | 1 | 1 | — | — | — | 1 |
| Obstructive jaundice | D041781 | EFO_1001068 | 1 | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gallbladder diseases | D005705 | EFO_0003832 | K82.9 | — | — | — | — | 2 | 2 |
| Cardiac catheterization | D006328 | — | — | — | — | 1 | 1 | ||
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | — | — | — | — | 1 | 1 |
| Critical illness | D016638 | — | — | — | — | 1 | 1 | ||
| Liver transplantation | D016031 | EFO_0010682 | — | — | — | — | 1 | 1 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | — | — | 1 | 1 |
| Intraoperative complications | D007431 | — | — | — | — | 1 | 1 | ||
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | — | — | — | 1 | 1 |
| Cytomegalovirus infections | D003586 | EFO_0001062 | B25 | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NEOSTIGMINE |
| INN | neostigmine bromide |
| Description | Neostigmine is a quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor. It has a role as an EC 3.1.1.7 (acetylcholinesterase) inhibitor and an antidote to curare poisoning. |
| Classification | Small molecule |
| Drug class | cholinesterase inhibitors (physostigmine type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)C(=O)Oc1cccc([N+](C)(C)C)c1 |
Identifiers
| PDB | — |
| CAS-ID | 59-99-4 |
| RxCUI | — |
| ChEMBL ID | CHEMBL278020 |
| ChEBI ID | 7514 |
| PubChem CID | 4456 |
| DrugBank | DB01400 |
| UNII ID | 005SYP50G5 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
Clinical Variant
No data
Financial
Bloxiverz - Avadel Pharmaceuticals
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 8,364 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
89 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more